These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 35947738)

  • 1. Glycated Haemogloin, Fasting Plasma Glucose, Plasminogen Activator Inhibitor Type-1, and Soluble Thrombomodulin Levels in Patients with Type 2 Diabetes Mellitus.
    Akwiwu E; Edem M; Akpotuzor J; Asemota E; Isong I
    Niger J Physiol Sci; 2021 Dec; 36(2):159-164. PubMed ID: 35947738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-challenge hyperglycaemia relates more strongly than fasting hyperglycaemia with carotid intima-media thickness: the RIAD Study. Risk Factors in Impaired Glucose Tolerance for Atherosclerosis and Diabetes.
    Hanefeld M; Koehler C; Henkel E; Fuecker K; Schaper F; Temelkova-Kurktschiev T
    Diabet Med; 2000 Dec; 17(12):835-40. PubMed ID: 11168325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasminogen activator inhibitor (PAI-1) activity is elevated in Asian and Caucasian subjects with non-insulin-dependent (type 2) diabetes but not in those with impaired glucose tolerance (IGT) or non-diabetic Asians.
    Nagi DK; Mohamed Ali V; Jain SK; Walji S; Yudkin JS
    Diabet Med; 1996 Jan; 13(1):59-64. PubMed ID: 8741814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postprandial peaks as a risk factor for cardiovascular disease: epidemiological perspectives.
    Bonora E
    Int J Clin Pract Suppl; 2002 Jul; (129):5-11. PubMed ID: 12166607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus.
    Kuzuya T; Nakagawa S; Satoh J; Kanazawa Y; Iwamoto Y; Kobayashi M; Nanjo K; Sasaki A; Seino Y; Ito C; Shima K; Nonaka K; Kadowaki T;
    Diabetes Res Clin Pract; 2002 Jan; 55(1):65-85. PubMed ID: 11755481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unmet Needs of Glycaemic Control and Risk Factors of Residual Hyperglycaemia in a Chinese Population with Type 2 Diabetes Initiating Basal Insulin: A Post Hoc Analysis of the FPG GOAL Study.
    Wang X; Wu G; Shen D; Zhang X; Yang W
    Adv Ther; 2022 Jun; 39(6):2820-2830. PubMed ID: 35430674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.
    Kruszynska YT; Yu JG; Olefsky JM; Sobel BE
    Diabetes; 2000 Apr; 49(4):633-9. PubMed ID: 10871202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A global study of the unmet need for glycemic control and predictor factors among patients with type 2 diabetes mellitus who have achieved optimal fasting plasma glucose control on basal insulin.
    Raccah D; Chou E; Colagiuri S; Gaàl Z; Lavalle F; Mkrtumyan A; Nikonova E; Tentolouris N; Vidal J; Davies M
    Diabetes Metab Res Rev; 2017 Mar; 33(3):. PubMed ID: 27606888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood glucose patterns in type 2 diabetic patients with optimal fasting plasma glucose but high HbA1c.
    Charoenhirunyingyos W; Nitiyanant W; Thabsang P; Sriussadaporn S; Vannasaeng S
    J Med Assoc Thai; 2011 Mar; 94(3):278-85. PubMed ID: 21560834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low fasting glucose-to-estimated average glucose ratio was associated with superior response to insulin degludec/aspart compared with basal insulin in patients with type 2 diabetes.
    Jang HN; Yang YS; Oh TJ; Koo BK; Lee SO; Park KS; Jang HC; Jung HS
    J Diabetes Investig; 2022 Jan; 13(1):85-93. PubMed ID: 34291584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of diagnostic discordance for non-diabetic hyperglycaemia and Type 2 diabetes using paired glycated haemoglobin measurements in a large English primary care population: cross-sectional study.
    Bachmann MO; Lewis G; John WG; Turner J; Dhatariya K; Clark A; Pascale M; Sampson M;
    Diabet Med; 2019 Nov; 36(11):1478-1486. PubMed ID: 31420897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of nateglinide and glibenclamide on prothrombotic factors in naïve type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial.
    Derosa G; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Cicero AF
    Intern Med; 2007; 46(22):1837-46. PubMed ID: 18025765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased plasminogen activator inhibitor-1 activity in offspring of type 2 diabetic patients: lack of association with plasma insulin levels.
    Gürlek A; Bayraktar M; Kirazli S
    Diabetes Care; 2000 Jan; 23(1):88-92. PubMed ID: 10857975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasminogen activator inhibitor-1 in nonobese subjects with non-insulin-dependent diabetes mellitus.
    Ito Y; Okeda T; Sato Y; Ito M; Sakata T
    Proc Soc Exp Biol Med; 1996 Mar; 211(3):287-91. PubMed ID: 8633110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the long-term durability and glycemic control of fasting plasma glucose and glycosylated hemoglobin for pioglitazone in Japanese patients with type 2 diabetes.
    Stringer F; DeJongh J; Enya K; Koumura E; Danhof M; Kaku K
    Diabetes Technol Ther; 2015 Mar; 17(3):215-23. PubMed ID: 25531677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors.
    Derosa G; Mugellini A; Ciccarelli L; Crescenzi G; Fogari R
    Clin Ther; 2003 Feb; 25(2):472-84. PubMed ID: 12749508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short- and long-term treatments with iloprost in diabetic patients with peripheral vascular disease: effects on the cardiovascular risk factor plasminogen activator inhibitor type-1.
    Cozzolino D; Coppola L; Masi S; Salvatore T; Sasso FC; De Lucia D; Gentile S; Torella R
    Eur J Clin Pharmacol; 1999 Sep; 55(7):491-7. PubMed ID: 10501817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of gliclazide on platelet aggregation and the plasminogen activator inhibitor type 1 level in patients with type 2 diabetes mellitus.
    Konya H; Hasegawa Y; Hamaguchi T; Satani K; Umehara A; Katsuno T; Ishikawa T; Miuchi M; Kohri K; Suehiro A; Kakishita E; Miyagawa J; Namba M
    Metabolism; 2010 Sep; 59(9):1294-9. PubMed ID: 20070990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between fasting plasma glucose and glycosylated hemoglobin: potential for false-positive diagnoses of type 2 diabetes using new diagnostic criteria.
    Davidson MB; Schriger DL; Peters AL; Lorber B
    JAMA; 1999 Apr; 281(13):1203-10. PubMed ID: 10199430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics of type 2 diabetic patients on basal insulin therapy with adequate fasting glucose control who do not achieve HbA1c targets.
    Mata-Cases M; Mauricio D; Franch-Nadal J
    J Diabetes; 2017 Jan; 9(1):34-44. PubMed ID: 26749415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.